Comparing Implementation and Effectiveness Outcomes for Two Implementation Strategies of the Keep It Up! Digital HIV Prevention Program: A Type 3 Hybrid Effectiveness-Implementation Trial
- PMID: 40826259
- PMCID: PMC12580418
- DOI: 10.1007/s10461-025-04838-0
Comparing Implementation and Effectiveness Outcomes for Two Implementation Strategies of the Keep It Up! Digital HIV Prevention Program: A Type 3 Hybrid Effectiveness-Implementation Trial
Abstract
This study sought to compare implementation and effectiveness outcomes for two delivery strategies of a digital HIV prevention intervention: community-based organization (CBO) versus direct-to-consumer (DTC). A type III hybrid effectiveness-implementation trial compared two implementation strategies of Keep It Up! (KIU! ) for young men who have sex with men (YMSM) (n = 2124). Data were collected at baseline and 12-weeks in 2019-2023. DTC enrolled more participants, but CBO recruited more Black (11.7% vs. 21.7%) and Latino YMSM (27.3% vs. 32.9%). CBO enrollees were at higher HIV risk based on condomless anal sex (p < .05) and rectal Gonorrhea rates (p < .01). Although pre-exposure prophylaxis (PrEP) use with adherence was 1.94 times higher at follow-up vs. baseline (p < .0001) across arms, PrEP increase was 1.60 times higher in CBO vs. DTC (p < .0001). CBO delivery averted more HIV infections per 100 people-years than DTC (1.65 vs. 0.62), but the cost of averting an HIV infection was higher in CBO than DTC ($983,029 vs. $173,313). Although CBOs were able to reach participants at higher HIV risk, the DTC strategy was estimated to cost less per infection averted and below established thresholds for cost savings. Findings must be interpreted within the context of data collection during the COVID-19 epidemic. More information about KIU! can be found at https://kiu.northwestern.edu/ .Trial registration: NCT03896776 (date of registration: 04/01/2019).
Keywords: Digital health interventions; HIV/AIDS; Men who have sex with men; Type III hybrid effectiveness implementation trial.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors have no competing interests to declare that are relevant to the content of this article. Ethical Approval: The trial was approved by the IRB at Northwestern University (STU00207476). All participants were informed of the aims of the study and of data protection; all participants consented to participate in our trial. Research Involving Human and /or Animal Participants: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Figures
References
-
- Centers for Disease Control and Prevention. HV Surveillance Supplemental Report: estimated HIV Incidence and Prevalence in the United States, 2018–2022. 2024. https://stacks.cdc.gov/view/cdc/156513
-
- Centers for Disease Control and Prevention. Compendium of evidence-based interventions and best practices for HIV prevention. 2024. https://www.cdc.gov/hiv/research/interventionresearch/compendium/index.html. Accessed 10 Feb 2024
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
